Bharat Biotech Phase III Trial of Corona Vaccine ‘Covaxin’ Starts

Muzaffarpur City
Corona Update

India is developing biotech covicin in partnership with ICMR-National Institute of Virology (NIV). Sources said the company had sought permission from the Drug Controller General of India (DCGI) on October 2 for the Phase III vaccine test. Ella said, we are working on another vaccine. It will be in the form of a drop through the nose. I think we will be able to provide this vaccine to the population by next year.

Ella said, ‘We have partnered with the Indian Council of Medical Research (ICMR) for the Kovid-19 vaccine. Phase III trial of this vaccine has started. He said that India Biotech is the only vaccine company in the world which has a biosafety level-3 (BSL3) production facility. Last month, the company said it had successfully completed an interim analysis of the first and second phase trials and was about to begin the third phase trial on 26,000 partners.

Phase III trials of Bharat Biotech’s Kovid-19 vaccine Kovaxin have begun. Krishna Ella, Chairman and Managing Director of the company gave this information on Monday. Addressing an event organized by the Indian School of Business through video conference, Ella said that the company is working on another vaccine for Kovid-19. It will be in the form of a drop through the nose. This vaccine will be ready by next year.








































































































	


	



					

					
Related Posts

					

													

								

									
			

				IRFCL CSR ACTIVITY IN MUZAFFARPUR 2			


											

										

											
इंडियन रेलवे फाइनेंस कॉरपोरेशन लिमिटेड के CSR कार्यक्रम के अंतर्गत  दिव्यांगजन उपकरण वितरण समारोह
										

										

											
इंडियन रेलवे फाइनेंस कॉरपोरेशन लिमिटेड के CSR कार्यक्रम के अंतर्गत दिव्यांगजन उपकरण वितरण समारोह का आयोजन स्थानीय डीआरसीसी भवन में…

										

									

								

							

														
														

								
							

												

				

				



	
		

			
Leave a Reply